Item 2.01 Completion of Acquisition or Disposition of Assets
Tauriga Sciences, Inc. (the “Company”) participated in a $15,000,000 underwritten public offering by Vistagen Therapeutics Inc. (NASDAQ: VTGN) (“Vistagen”), which closed on December 13, 2017. The Company invested $480,000 USD of its net cash position and purchased 320,000 registered shares of Vistagen common stock, as well as warrants exercisable immediately for a period of five (5) years from the date of issuance for up to 320,000 additional shares of common stock of Vistagen. The Warrants carry an exercise price of $1.50 per share, and do not incorporate a cashless exercise feature. The Company is in possession of the registered securities as of the closing date.
